Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Equity Ratio (2022 - 2025)

Axsome Therapeutics' Equity Ratio history spans 4 years, with the latest figure at 0.13 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 27.63% year-over-year to 0.13; the TTM value through Dec 2025 reached 0.13, up 27.63%, while the annual FY2025 figure was 0.13, 27.63% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.13 at Axsome Therapeutics, up from 0.11 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.46 in Q3 2022 and bottomed at 0.08 in Q2 2022.
  • The 4-year median for Equity Ratio is 0.18 (2024), against an average of 0.23.
  • The largest annual shift saw Equity Ratio skyrocketed 441.51% in 2023 before it tumbled 69.11% in 2024.
  • A 4-year view of Equity Ratio shows it stood at 0.33 in 2022, then fell by 1.77% to 0.32 in 2023, then crashed by 69.11% to 0.1 in 2024, then grew by 27.63% to 0.13 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Equity Ratio are 0.13 (Q4 2025), 0.11 (Q3 2025), and 0.11 (Q2 2025).